中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

40 records (took 0.039 seconds)

    WDRPUH Epitope Peptides and Vaccines Containing the Same
    31.
    发明申请
    WDRPUH Epitope Peptides and Vaccines Containing the Same 审中-公开
    WDRPUH表位肽和含有其的疫苗

    公开(公告)号：US20130315942A1

    公开(公告)日：2013-11-28

    申请号：US13900720

    申请日：2013-05-23

    Applicant: OncoTherapy Science, Inc.

    Inventor： Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC: C07K14/47 ,  C12N5/0783 ,  A61K38/17 ,  C12N5/0784

    CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K38/1764 ,  A61K39/0011 ,  C07K14/47 ,  C07K14/4748 ,  C12N5/0638 ,  C12N5/0639

    Abstract: The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.

    Abstract translation: 本发明提供了含有SEQ ID NO：1,2,3,4，16，17，30，31，34，36，37，40，41，45，49，55，57和61的氨基酸序列的肽 ，以及含有上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失，插入或添加，但仍具有细胞毒性T细胞诱导性。 本发明还提供了用于治疗或预防肿瘤的药物，其含有这些肽的药物。 本发明的肽也可以用作疫苗。

    Peptide Vaccines For Cancers Expressing Tumor-Associated Antigens
    32.
    发明申请
    Peptide Vaccines For Cancers Expressing Tumor-Associated Antigens 失效
    表达肿瘤相关抗原的癌症疫苗

    公开(公告)号：US20130189291A1

    公开(公告)日：2013-07-25

    申请号：US13744354

    申请日：2013-01-17

    Applicant: Oncotherapy Science, Inc.

    Inventor： Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura

    IPC: C07K7/06

    CPC classification number: C07K4/12 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/47 ,  G01N2500/00

    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.

    Abstract translation: 本发明提供了具有SEQ ID NO：19,22,30,34,344,358,41,44,46,48,78,376,49,48,78,376,479,48和78的氨基酸序列的肽。 110,111,387,112,394,114,116,117,121,345,133,135,137,426,143,147,148,149,150,152,153,154,156,160,161， 162,163,166,174,178,186,194,196,202,210,213,214,217,223,227,228,233,254,271,272或288以及具有上述的肽的肽， 提供其中1,2或几个（例如，至多5个）氨基酸被取代，缺失或添加的上述氨基酸序列，条件是肽具有细胞毒性T细胞诱导性。 本发明还提供用于治疗或预防与CDH3，EPHA4，ECT2，HIG2，INHBB，KIF20A，KNTC2，TTK和/或URLC10的过表达相关的疾病的药物，例如。 含有这些肽中的一种或多种的活性成分的癌症。 本发明的肽可作为疫苗进一步发挥作用。

    CDCA1 epitope peptides and vaccines containing the same
    33.
    发明授权
    CDCA1 epitope peptides and vaccines containing the same 有权

    公开(公告)号：US10711047B2

    公开(公告)日：2020-07-14

    申请号：US15176444

    申请日：2016-06-08

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura

    IPC: A61K39/00 ,  C07K14/47 ,  C12N5/0783 ,  C07K7/06 ,  A61K38/00

    Abstract: Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the CDCA1 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, breast cancer, bladder cancer, esophageal cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

    HJURP peptides and vaccines including the same
    36.
    发明授权
    HJURP peptides and vaccines including the same 有权
    HJURP肽和疫苗包括相同

    公开(公告)号：US09403890B2

    公开(公告)日：2016-08-02

    申请号：US14205163

    申请日：2014-03-11

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC: C07K7/00 ,  A61K38/08 ,  C07K14/47 ,  C07K7/06 ,  C07K16/18 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00

    CPC classification number: C07K14/4748 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00 ,  C07K7/06 ,  C07K16/18

    Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding the peptides as well as pharmaceutical agents, substances and/or compositions that include any of the peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find utility in the treatment of cancers, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.

    Abstract translation: 本文描述了衍生自SEQ ID NO：50的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗。 本发明的肽包括上述氨基酸序列及其修饰形式，只要它们保留原始序列所需的细胞毒性T细胞诱导能力即可。 还提供了编码肽的核酸以及包括任何肽或核酸的药剂，物质和/或组合物。 本发明的肽，核酸，药物，物质和组合物可用于治疗癌症，包括例如AML，膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠癌，食道癌， 扩散型胃癌，肝癌，NSCLC，淋巴瘤，骨肉瘤，卵巢癌，胰腺癌，前列腺癌，肾癌，SCLC，软组织肿瘤和睾丸肿瘤。

    PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR-ASSOCIATED ANTIGENS
    37.
    发明申请
    PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR-ASSOCIATED ANTIGENS 审中-公开
    用于表达肿瘤相关抗原的癌症的肽疫苗

    公开(公告)号：US20160200764A1

    公开(公告)日：2016-07-14

    申请号：US14989741

    申请日：2016-01-06

    Applicant: OncoTherapy Science, Inc.

    Inventor： Takuya Tsunoda ,  Ryuji Ohsawa

    IPC: C07K7/06 ,  A61K39/00

    CPC classification number: C07K4/12 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/47 ,  G01N2500/00

    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.

    Abstract translation: 本发明提供了具有SEQ ID NO：19,22,30,34,344,358,41,44,46,48,78,376,49,48,78,376,479,48和78的氨基酸序列的肽。 110,111,387,112,394,114,116,117,121,345,133,135,137,426,143,147,148,149,150,152,153,154,156,160,161， 162,163,166,174,178,186,194,196,202,210,213,214,217,223,227,228,233,254,271,272或288以及具有上述的肽的肽， 提供其中1,2或几个（例如，至多5个）氨基酸被取代，缺失或添加的上述氨基酸序列，条件是肽具有细胞毒性T细胞诱导性。 本发明还提供用于治疗或预防与CDH3，EPHA4，ECT2，HIG2，INHBB，KIF20A，KNTC2，TTK和/或URLC10的过表达相关的疾病的药物，例如。 含有这些肽中的一种或多种的活性成分的癌症。 本发明的肽可作为疫苗进一步发挥作用。

    FOXM1 PEPTIDE AND MEDICINAL AGENT COMPRISING THE SAME
    38.
    发明申请
    FOXM1 PEPTIDE AND MEDICINAL AGENT COMPRISING THE SAME 审中-公开
    FOXM1肽和药物包括它们

    公开(公告)号：US20150265689A1

    公开(公告)日：2015-09-24

    申请号：US14729752

    申请日：2015-06-03

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Yasuharu Nishimura ,  Kazunori Yokomine ,  Takuya Tsunoda ,  Yusuke Nakamura

    IPC: A61K39/00 ,  C12N5/0783 ,  C07K7/06

    CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/06 ,  C07K7/08 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2501/998 ,  C12N2502/11

    Abstract: An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.

    Abstract translation: 本发明的目的是提供一种能够通过鉴定可以激活癌细胞破坏性的FOXM1衍生的肽来靶向大约30％的高度表达日本人中的叉头盒M1（FOXM1）的各种癌症患者的癌症免疫治疗的手段 人类杀伤T细胞通过结合HLA-A2。 本发明提供下述（A）或（B）的肽：（A）包含SEQ ID NO：1〜3中任一项所述的氨基酸序列的肽; （B）包含SEQ ID NO：1至3中任一项的氨基酸序列的肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，并且其中 肽显示出细胞毒性（杀伤）T细胞诱导活性。

    PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR-ASSOCIATED ANTIGENS
    39.
    发明申请
    PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR-ASSOCIATED ANTIGENS 审中-公开

    公开(公告)号：US20140141027A1

    公开(公告)日：2014-05-22

    申请号：US14079144

    申请日：2013-11-13

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura

    IPC: C07K7/06

    CPC classification number: C07K4/12 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/47 ,  G01N2500/00

    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.

    FOXM1 PEPTIDE AND MEDICINAL AGENT COMPRISING THE SAME
    40.
    发明申请
    FOXM1 PEPTIDE AND MEDICINAL AGENT COMPRISING THE SAME 审中-公开
    FOXM1肽和药物包括它们

    公开(公告)号：US20140023672A1

    公开(公告)日：2014-01-23

    申请号：US14036879

    申请日：2013-09-25

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Yasuharu Nishimura ,  Kazunori Yokomine ,  Takuya Tsunoda ,  Yusuke Nakamura

    IPC: C07K7/08

    CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/06 ,  C07K7/08 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2501/998 ,  C12N2502/11

    Abstract: An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below:(A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.

    Abstract translation: 本发明的目的是提供一种能够通过鉴定可以激活癌细胞破坏性的FOXM1衍生的肽来靶向大约30％的高度表达日本人中的叉头盒M1（FOXM1）的各种癌症患者的癌症免疫治疗的手段 人类杀伤T细胞通过结合HLA-A2。 本发明提供下述（A）或（B）的肽：（A）包含SEQ ID NO：1〜3中任一项所述的氨基酸序列的肽; （B）包含SEQ ID NO：1至3中任一项的氨基酸序列的肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，并且其中 肽显示出细胞毒性（杀伤）T细胞诱导活性。

Patent Agency Ranking